Status:

COMPLETED

Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants

Lead Sponsor:

Nicolai Jacob Wewer Albrechtsen

Conditions:

Glucose Metabolism

Glucagon

Eligibility:

All Genders

25-70 years

Phase:

NA

Brief Summary

In this study the investigators will investigate the acute effects of increasing glucagon exposure on metabolic parameters in healthy participants. Participants will participate in one study day. Aft...

Detailed Description

Ten participants with normal health will be included, and each participant will participate in one study day. Participants will arrive after an overnight fast and will be placed in a hospital bed in ...

Eligibility Criteria

Inclusion

  • Capable of understanding the participant information and signing the consent form
  • Between 25 and 70 years of age at the time of screening
  • Body mass index (BMI) ≤ 25 kg/m2 at the time of screening

Exclusion

  • Enrolment in other research projects that might interfere with the study
  • Diabetes diagnosis (type 1 and 2)
  • Pregnancy or breastfeeding
  • Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
  • Impaired liver function defined as either alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥ 2 times normal values
  • Kidney disease defined as serum creatinine levels ≥ 126 μmol/L for male and ≥ 111 μmol/L for female
  • Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic
  • Active or recent malignant disease
  • Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
  • Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol

Key Trial Info

Start Date :

March 31 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 19 2025

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT06921824

Start Date

March 31 2025

End Date

September 19 2025

Last Update

December 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark

Copenhagen, Denmark, 2400